CA3074139A1 - Compounds and compositions for ire1 inhibition - Google Patents

Compounds and compositions for ire1 inhibition Download PDF

Info

Publication number
CA3074139A1
CA3074139A1 CA3074139A CA3074139A CA3074139A1 CA 3074139 A1 CA3074139 A1 CA 3074139A1 CA 3074139 A CA3074139 A CA 3074139A CA 3074139 A CA3074139 A CA 3074139A CA 3074139 A1 CA3074139 A1 CA 3074139A1
Authority
CA
Canada
Prior art keywords
amino
pyrazin
imidazo
naphthalen
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3074139A
Other languages
English (en)
French (fr)
Inventor
Richard M. Keenan
Bradley J. Backes
Dustin J. MALY
Charles Reynolds
Ben Whittaker
Jamie Knight
Jon Sutton
George Hynd
Feroz R. PAPA
Scott A. OAKES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Optikira LLC
Original Assignee
University of California San Diego UCSD
Optikira LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD, Optikira LLC filed Critical University of California San Diego UCSD
Publication of CA3074139A1 publication Critical patent/CA3074139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3074139A 2017-09-01 2018-08-31 Compounds and compositions for ire1 inhibition Pending CA3074139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (1)

Publication Number Publication Date
CA3074139A1 true CA3074139A1 (en) 2019-03-07

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3074139A Pending CA3074139A1 (en) 2017-09-01 2018-08-31 Compounds and compositions for ire1 inhibition

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
EP3930718A4 (en) * 2019-02-27 2022-10-05 Optikira LLC Pyrazolopyridine compounds for ire1 inhibition
US20230331719A1 (en) * 2020-08-07 2023-10-19 Optikira, LLC Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
EP4460492A1 (en) * 2022-01-07 2024-11-13 (INSERM) Institut National de la Santé et de la Recherche Médicale Compounds containing a hydroxyphenyl moiety and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
MX2012011504A (es) 2010-04-05 2013-01-18 Mannkind Corp Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
RU2015115631A (ru) * 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS

Also Published As

Publication number Publication date
US20200354367A1 (en) 2020-11-12
KR20200066301A (ko) 2020-06-09
EP3675858A2 (en) 2020-07-08
BR112020004226A2 (pt) 2020-11-17
CN111526877B (zh) 2023-08-25
SG11202001609RA (en) 2020-03-30
US11649237B2 (en) 2023-05-16
AU2018326721A1 (en) 2020-03-12
EP3675858B1 (en) 2023-04-26
CN111526877A (zh) 2020-08-11
WO2019046711A3 (en) 2020-04-02
IL272845B2 (en) 2023-12-01
RU2020112425A (ru) 2021-10-04
IL272845A (en) 2020-04-30
ZA202001320B (en) 2023-10-25
RU2020112425A3 (enExample) 2022-03-31
MX2020002322A (es) 2020-10-05
EP3675858A4 (en) 2021-03-17
AU2018326721B2 (en) 2022-12-01
JP2020532589A (ja) 2020-11-12
WO2019046711A2 (en) 2019-03-07
IL272845B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
CN112601750B (zh) Ptpn11（shp2）抑制剂
EP3675858B1 (en) Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition
WO2019204354A1 (en) Spirocyclic compounds
CA3016182A1 (en) Substituted indole mcl-1 inhibitors
AU2017226004A1 (en) Inhibitors of WDR5 protein-protein binding
AU2016382372B2 (en) Sulfonamide derivative and preparation method and use thereof
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
AU2018285131A1 (en) Heteroaromatic compounds as Vanin inhibitors
CA3045242A1 (en) Heteroarylphenoxy benzamide kappa opioid ligands
CA3005236C (en) Heterocyclic compounds for the inhibition and treatment of sphingosine-1-phosphate mediated diseases
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
BR112013017164B1 (pt) composto e composição farmacêutica
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
WO2017073743A1 (ja) 三環性化合物
CN118159535A (zh) 小分子sting拮抗剂
KR20240046742A (ko) 소분자 sting 길항제
CA3181351A1 (en) Nampt modulators
EP3749671A1 (en) [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
CA3131386A1 (en) Imidazolopyrazine compounds for ire1 inhibition
CA3131388A1 (en) Pyrazolopyridine compounds for ire1 inhibition
KR20240046553A (ko) Sting 길항제로서의 소분자 우레아 유도체
WO2024040190A1 (en) Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230822